N-(2-氨基乙基)-5-氯-2-吡啶甲酰胺-盐酸 | 52617-25-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: N-(2-氨基乙基)-5-氯-2-吡啶甲酰胺-盐酸
• 英文名称: psychotridine C
• 英文别名: Psychotridin；1,1',1'',1''',1''''-pentamethyl-2,3,8,8a,2',3',8',8'a,2'',3'',8'',8''a,2''',3''',8''',8'''a,2'''',3'''',8'''',8''''a-eicosahydro-1H,1'H,1''H-1'''H,1''''H-[3a,7';3'a,3''a;7'',3'''a;7''',3''''a]quinque(pyrrolo[2,3-b]indole)；Psychotridine；3-methyl-5,8b-bis[3-methyl-5-(3-methyl-1,2,3a,4-tetrahydropyrrolo[2,3-b]indol-8b-yl)-1,2,3a,4-tetrahydropyrrolo[2,3-b]indol-8b-yl]-1,2,3a,4-tetrahydropyrrolo[2,3-b]indole
• CAS: 52617-25-1
• 化学式: C₅₅H₆₂N₁₀
• 分子量: 863.164
• InChiKey: DVJSMVZSIBHXAO-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于DMSO

计算性质

• 辛醇/水分配系数(LogP)：
  9.4
• 重原子数：
  65
• 可旋转键数：
  4
• 环数：
  15.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  76.4
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• COMPOUND AND METHOD FOR REDUCING INFLAMMATION, PAIN, ALLERGY, FLU AND COLD SYMPTOMS
  申请人：Kariman Alexander

  公开号：US20180271924A1

  公开（公告）日：2018-09-27

  The present invention relates to pharmaceutical and nutraceutical compounds and methods for reducing inflammation, blood sugar, gastric acid, symptoms of allergy, common cold and flu, as well as treating infections and pain associated with trauma, medical procedure, and diseases and disorders in subjects in need thereof. The compounds and methods proposed by this invention are related to essentially a mixture of naturally accruing and/or synthetic substances in certain ratios, administration protocols, and delivery systems that amplify their medicinal qualities and reduce side effects, making their clinical application feasible.
• BIASED NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE

  公开号：US20220016105A1

  公开（公告）日：2022-01-20

  Described herein are compounds that can be capable of modulating an N-methyl-D-aspartate (NMDA) receptor. In some embodiments, the compound(s) can be a biased modulator of an NMDA receptor. In some embodiments, the compound(s) can be a biased allosteric modulator of an NMDA receptor. Also described herein are methods of treating an NMDA-mediated disease by administering one or more of the compounds described herein. In some embodiments, the compounds can be effective to treat a neurobiological or psychiatric disease or disorder.
• [EN] BIASED NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE RÉCEPTEURS NMDA POLARISÉS ET LEURS UTILISATIONS
  申请人：EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE

  公开号：WO2020102443A1

  公开（公告）日：2020-05-22

  Described herein are compounds that can be capable of modulating an N-methyl-D- aspartate (NMD A) receptor. In some embodiments, the compound(s) can be a biased modulator of an NMDA receptor. In some embodiments, the compound(s) can be a biased allosteric modulator of an NMDA receptor. Also described herein are methods of treating an NMDA- mediated disease by administering one or more of the compounds described herein. In some embodiments, the compounds can be effective to treat a neurobiological or psychiatric disease or disorder.